title: Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab.
abstract: A 55 year old man with chronic lymphocytic leukaemia (CLL) and rheumatoid arthritis (RA), treated for four years with methotrexate (MTX), who developed a B cell non-Hodgkin's lymphoma (B-NHL), is described. The tumour was localised to the shoulder and axillary lymph nodes, and positive for Epstein-Barr viral antigens. After failure of radiation and chemotherapy, a complete remission was achieved with a combination of antibody treatment (rituximab) and EPOCH. The development of a second malignancy in a patient with RA receiving MTX has not been described before. The summation of T cell deficiencies induced by MTX, CLL, and RA may all have contributed to the development of the B-NHL.
authors.affiliation: Department of Rheumatology, Washington Hospital Centre, Washington, DC, USA.
authors.forename: M
authors.initials: M
authors.lastname: Stewart
authors.forename: V
authors.initials: V
authors.lastname: Malkovska
authors.forename: J
authors.initials: J
authors.lastname: Krishnan
authors.forename: L
authors.initials: L
authors.lastname: Lessin
authors.forename: W
authors.initials: W
authors.lastname: Barth
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016867:Immunocompromised Host; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000209:etiology; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D000069283:Rituximab; D008727:Methotrexate